:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/SUEOMCTOCBAY5KNNJCX32LMCPY.jpeg)
The Chinese pharmaceutical company Clover Biopharmaceuticals announced that it has developed a vaccine whose trials show an efficacy of 79% in protecting the patient from complications of any severity caused by the Delta variant of SARS-CoV-2, local media reported.
Likewise, the pharmaceutical company – which plans to supply 414 million doses to the COVAX program – assured that the vaccine, called SCB-19, is 92% and 59% effective against the Gamma and Mu variants, respectively.
The general efficacy against complications of any severity caused by the coronavirus in any of the.
According to Clover, it is the first vaccine to show general efficacy against these three variants.
When it comes to preventing hospitalization for serious complications derived from SARS-CoV-2 in any of these three variants, the pharmaceutical company said.
More than 30,000 adults in Brazil, Colombia, the Philippines, South Africa and Belgium participated in the clinical trials and received the vaccine, which is given in two doses to be injected 21 days apart.
The study was funded by the Coalition for the Promotion of Innovations for Epidemic Preparedness (CEPI), an organization that contributed 328 million dollars (280 million euros) to carry it out.
CEPI is a partner of Gavi, the global alliance for public-private vaccines that participates together with the World Health Organization (WHO) in the COVAX project, which it pursues.
CEPI announced last June that it had reached a purchase agreement with Clover whereby the Chinese company will provide COVAX with 414 million doses of vaccines for global use between this year and next, once the Chinese Government and the WHO approve its use.
